14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ABCL vs RAPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.14 (27.6x Forward P/E, -1550.0% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs RAPT. Trailing 12-month operating profitability (ABCL -1550.0% vs RAPT 0.0%) and valuation multiples (ABCL 27.6x vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABCL vs RAPT Key Questions & Quantitative Answers
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ABCL carries a Unified Composite Score of 63.3/100 (BUY) at $11.14 (27.6x Forward P/E, -1550.0% operating margin), whereas RAPT carries 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin). Technically, ABCL sits in a Neutral phase (RSI 43.3, CONSOLIDATION options structure) and RAPT sits in a Markup phase (RSI 79.7, UNCLASSIFIED options structure).
ABCL leads the Growth & Scale pillar: ABCL posts -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABCL generates $66M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, ABCL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.
ABCL screens cheaper on headline valuation multiples. ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABCL (-17.3% ROE) versus RAPT (-85.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ABCL carries 84.0% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.30β · 87% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.